Evidence map›Paper›PMID 39459325›Full record

ArticleMolecules (Basel, Switzerland)2024

Thiazolidinedione-Conjugated Lupeol Derivatives as Potent Anticancer Agents Through a Mitochondria-Mediated Apoptotic Pathway.

Siqi Deng, Yinxu Zhao, Xiaoshan Guo, Xian Hong, Gang Li, Yuchun Wang, Qingyi Li, Ming Bu, Ming Wang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siqi DengCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Yinxu ZhaoCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Xiaoshan GuoCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Xian HongResearch Institute of Medicine & Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Gang LiResearch Institute of Medicine & Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Yuchun WangCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Qingyi LiCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
Ming BuCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.ORCID 0000-0001-9752-0886
Ming WangCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.

Funding

Fundamental Research Funds for Education Department of Heilongjiang Province 2020-KYYWF-0024
6 · The paper itself

Abstract

To improve the potential of lupeol against cancer cells, a privileged structure, thiazolidinedione, was introduced into its C-3 hydroxy group with ester, piperazine-carbamate, or ethylenediamine as a linker, and three series of thiazolidinedione-conjugated compounds (

Indexed as

Antineoplastic AgentsApoptosisMitochondriaPentacyclic TriterpenesThiazolidinedionesA549 CellsCell Line, TumorCell ProliferationHep G2 CellsHumansLupanesMCF-7 CellsMolecular StructureSignal TransductionStructure-Activity Relationship2,4-thiazolidinedioneAntineoplastic AgentsLupaneslupeolPentacyclic TriterpenesThiazolidinedionesantitumorapoptotichybridslupeolthiazolidinedionetriterpenoid

Identifiers

PMID39459325
PMCPMC11510666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.